Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, was issued on February 2, 2026. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of January 31, 2026, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
- Issued Share Capital: 4,316,103,805 Ordinary Shares of 31½ pence each.
- Treasury Shares: 240,019,489 Ordinary Shares.
- Total Voting Rights: 4,076,084,316.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document focuses solely on the current state of share capital and voting rights.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The Company Secretary noted that the total voting rights figure may be used by shareholders to determine notification requirements under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,076,084,316) against internal records for compliance with FCA disclosure thresholds.
- Confirm the count of Treasury Shares (240,019,489) held as of January 31, 2026.
- Ensure the issued share capital figure (4,316,103,805) aligns with the latest annual report (Form 20-F).